Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform"). The Hematology MDT Platform...
Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare
TOKYO, Sept. 17, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, today celebrates its 100th anniversary. The company, based in Tokyo, boasts over 25,000 associates worldwide, providing products and services to more than 160 countries and regions across the globe. Terumo started in 1921 as a...
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys' ovarian cancer vaccine and is beginning the next...
Vieworks to Showcase its Complete Dental Detector Lineup at IDS 2021
ANYANG, South Korea, Sept. 17, 2021 /PRNewswire/ -- Vieworks, a global leader in the X-ray imaging industry, presents its complete dental detector lineups at the International Dental Show (IDS) 2021 (hall 11.2 P/R 28/29) from 22 to 25 September. IDS is the world's biggest trade fair for dentistry and dental technology, which takes place in Cologne, Germany every two...
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan)...
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 2 study in Chinese patients with advanced cholangiocarcinoma were released today at the European...
CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021
Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy The data showed that sugemalimab demonstrated a statistically significant and clinically meaningful improvement in the Blinded Independent Central Review (BICR) assessed PFS. The risk of...
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") and SinoMab BioScience Limited (stock code: 3681.HK "SinoMab") to develop, produce and commercialize XNW1011 (referred as "SN1011" by SinoMab), a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, globally for the treatment...
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expected to be announced in 2022 SEONGNAM,...
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 17, 2021 /PRNewswire/ -- PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with...













